NTV Asset Management 13F: New $3.4M Stake in CRSP

NTV Asset Management opened a new position in CRISPR Therapeutics AG (NasdaqGM: CRSP), buying 61,443 shares valued at about $3,399,027. The investment came to light in a Form 13F filing with the Securities and Exchange Commission on October 23, 2026.

CRSP CRISPR Therapeutics AG

$49.39 ▼ -8.15% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in NTV Asset Management's CRISPR Therapeutics Position

The fund started a brand-new holding in the gene-editing company during the period, ending up with 61,443 shares.

Other Institutional Activity in CRISPR Therapeutics

ARK Investment Management, LLC reduced its holdings by 1,853,267 shares, ending with 9,460,939 shares worth about $467,275,771. Orbis Allan Gray Ltd cut its stake by 657,026 shares to hold 5,449,161 shares valued at about $269,134,058. GSK plc kept its position steady at 3,220,627 shares worth approximately $159,066,765. SR One Capital Management, LP held its stake unchanged at 2,038,763 shares valued at about $100,694,503. Two Sigma Investments, LP grew its holdings by 505,572 shares, ending with 1,988,621 shares worth about $98,217,989.

CRISPR Therapeutics AG Stock Down 2.2%

The stock closed at $49.39 on October 23, 2026, and recently traded around $49.39 as of October 24, 2026. The shares sit below their 52-week high of $68.71 and above their 52-week low of $44.12.

Recent Earnings

CRISPR Therapeutics posted trailing-twelve-month revenue of $13,392,000 with a year-over-year revenue growth rate of 1041.4%. The company reported a negative trailing earnings per share of $4.74 and a return on equity of -26.1%. The next earnings release is scheduled for November 9, 2026.

Insider Buying and Selling at CRISPR Therapeutics AG

Director Ali Behbahani sold 13,679 shares on September 17, 2026, at an average price of $57.09 for a total of $780,935. General Counsel James R. Kasinger sold 10,400 shares on September 22, 2026, at $60.24 for $626,460, and later sold 1,990 shares on October 6, 2026, at $60.04 for $119,481. Chief Executive Officer Samarth Kulkarni sold 47,837 shares on October 19, 2026, at an average price of $49.78 for a total of $2,381,326.

Analysts Set New Price Targets

Citigroup maintained a buy rating on August 4, 2026, while lifting its target to $88.00 from $82.00. Citizens reiterated a market outperform rating with an $80.00 target on August 25, 2026, and again on August 31, 2026. Needham reiterated a buy rating with an $82.00 target on August 31, 2026. UBS initiated coverage with a neutral rating and a $52.00 target on October 15, 2026. Across the broader analyst community, the stock holds a consensus buy rating with a mean price target of $85.63 based on 19 opinions.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a Zug, Switzerland-based biotechnology company focused on creating gene-based medicines for serious human conditions. It relies on a proprietary gene-editing platform to make precise alterations to genomic DNA sequences.

Bottom Line

NTV Asset Management's new stake adds to the ongoing institutional activity surrounding the biotech firm. Investors will look toward the upcoming earnings report on November 9, 2026, for further details on financial progress and pipeline updates.